These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 33493594

  • 1. 1α,25-Dihydroxyvitamin D3 synergistically enhances anticancer effects of ginsenoside Rh2 in human prostate cancer cells.
    Ben-Eltriki M, Deb S, Guns EST.
    J Steroid Biochem Mol Biol; 2021 May; 209():105828. PubMed ID: 33493594
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
    Zhao XY, Peehl DM, Navone NM, Feldman D.
    Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
    [Abstract] [Full Text] [Related]

  • 4. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
    Banwell CM, Singh R, Stewart PM, Uskokovic MR, Campbell MJ.
    Recent Results Cancer Res; 2003 Jul; 164():83-98. PubMed ID: 12899515
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
    Zhao XY, Ly LH, Peehl DM, Feldman D.
    Endocrinology; 1999 Mar; 140(3):1205-12. PubMed ID: 10067845
    [Abstract] [Full Text] [Related]

  • 7. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [Abstract] [Full Text] [Related]

  • 8. Ginsenoside-mediated blockade of 1α,25-dihydroxyvitamin D3 inactivation in human liver and intestine in vitro.
    Deb S, Chin MY, Adomat H, Guns ES.
    J Steroid Biochem Mol Biol; 2014 May; 141():94-103. PubMed ID: 24486455
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
    Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG.
    Recent Results Cancer Res; 2003 May; 164():273-88. PubMed ID: 12899529
    [Abstract] [Full Text] [Related]

  • 11. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity.
    Swami S, Krishnan AV, Peehl DM, Feldman D.
    Mol Cell Endocrinol; 2005 Sep 28; 241(1-2):49-61. PubMed ID: 15955619
    [Abstract] [Full Text] [Related]

  • 12. Vitamin B12 enhances the antitumor activity of 1,25-dihydroxyvitamin D3 via activation of caspases and targeting actin cytoskeleton.
    Atoum MF, Alzoughool FE, Al-Mazaydeh ZA, Rammaha MS, Tahtamouni LH.
    Tumour Biol; 2022 Sep 28; 44(1):17-35. PubMed ID: 35180142
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth.
    Gavrilov V, Steiner M, Shany S.
    Anticancer Res; 2005 Sep 28; 25(5):3425-9. PubMed ID: 16101159
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer.
    Flanagan JN, Zheng S, Chiang KC, Kittaka A, Sakaki T, Nakabayashi S, Zhao X, Spanjaard RA, Persons KS, Mathieu JS, Holick MF, Chen TC.
    Anticancer Res; 2009 Sep 28; 29(9):3547-53. PubMed ID: 19667147
    [Abstract] [Full Text] [Related]

  • 16. Induction of apoptosis and inhibition of prostate and breast cancer growth by BGP-15, a new calcipotriene-derived vitamin D3 analog.
    Berkovich L, Ben-Shabat S, Sintov AC.
    Anticancer Drugs; 2010 Jul 28; 21(6):609-18. PubMed ID: 20335794
    [Abstract] [Full Text] [Related]

  • 17. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
    Barreto AM, Schwartz GG, Woodruff R, Cramer SD.
    Cancer Epidemiol Biomarkers Prev; 2000 Mar 28; 9(3):265-70. PubMed ID: 10750664
    [Abstract] [Full Text] [Related]

  • 18. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.
    Xie X, Eberding A, Madera C, Fazli L, Jia W, Goldenberg L, Gleave M, Guns ES.
    J Urol; 2006 May 28; 175(5):1926-31. PubMed ID: 16600800
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.